Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$75.69−$0.2700 (−0.36%) on the dayAs of the close; data may be delayed.
TARS price, last 12 months
Key stats
- Previous close
- $75.96
- Open
- $75.78
- Day range
- $73.85 – $76.17
- 52-week range
- $53.89 – $91.53
- Volume
- 483.9K
- Avg volume (20 days)
- 767.3K
- Market cap
- $3.5B
Performance
1W−3.1%
1M+7.1%
3M+20.3%
6M+12.6%
YTD−7.6%
1Y+37.0%
vs S&P 500, 1Y+20.2 pts
Technicals and fundamentals
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $3.5B